PDF
Kurs
+5,58%
Likviditet
9,09 MNOK
Kalender
| Est. tid* | ||
| 2026-11-05 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-14 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-29 | N/A | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2026-05-28 | N/A | Årsstämma |
| 2026-05-07 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-12 | - | Bokslutskommuniké 2025 |
| 2025-11-06 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-14 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2025-05-27 | - | Årsstämma |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-26 | - | Årsstämma |
| 2024-06-06 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-01 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-07 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2023-06-06 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-23 | - | Årsstämma |
| 2022-05-27 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-01-27 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2021-05-20 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-19 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2020-05-14 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2020-01-06 | - | Extra Bolagsstämma 2020 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2019-05-15 | - | Årsstämma |
| 2019-04-30 | - | Kvartalsrapport 2019-Q1 |
| 2019-01-30 | - | Bokslutskommuniké 2018 |
| 2018-10-18 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-09 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2018-05-07 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-01 | - | Bokslutskommuniké 2017 |
| 2017-10-19 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2017-05-11 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-10-26 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2016-05-11 | - | Årsstämma |
| 2016-04-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-11 | - | Kapitalmarknadsdag 2016 |
| 2016-02-11 | - | Bokslutskommuniké 2015 |
| 2015-11-03 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-13 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2015-05-12 | - | Årsstämma |
| 2015-05-05 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | Bokslutskommuniké 2014 |
| 2014-11-05 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-15 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2014-05-14 | - | Årsstämma |
| 2014-04-30 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-14 | - | Bokslutskommuniké 2013 |
| 2013-11-01 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-09 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-13 | - | Kapitalmarknadsdag 2013 |
| 2013-05-28 | - | X-dag ordinarie utdelning |
| 2013-05-27 | - | Årsstämma |
| 2013-05-07 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-01 | - | Extra Bolagsstämma 2013 |
| 2013-01-07 | - | Bokslutskommuniké 2012 |
| 2012-11-06 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-10 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-07 | - | Årsstämma |
| 2012-05-07 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
| 2012-05-07 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-21 | - | Bokslutskommuniké 2011 |
| 2011-11-08 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-10 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-13 | - | Årsstämma |
| 2011-05-13 | - | Kvartalsrapport 2011-Q1 |
| 2011-05-12 | - | X-dag ordinarie utdelning |
| 2011-02-17 | - | Bokslutskommuniké 2010 |
| 2010-11-12 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-10 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-11 | - | Kvartalsrapport 2010-Q1 |
| 2010-05-04 | - | Årsstämma |
| 2010-03-03 | - | Bokslutskommuniké 2009 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Tromsø, Norway, February 12, 2026 - ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet.
Q4 2025 Highlights
- Total revenue: NOK 34.7 million (Q4 2024: NOK 26.4 million), +31% year-on-year
- Sales revenue: NOK 34.1 million (Q4 2024: NOK 24.5 million), +39% year-on-year
- Constant currency sales: NOK 36.3 million, +46%
- EBITDA: NOK 8.3 million (Q4 2024: NOK 2.5 million)
- EBITDA margin: 24% (Q4 2024: 11%)
Q4 marked a strong close to the year, driven by continued penetration in Biomanufacturing and robust performance in Molecular Tools.
Full Year 2025 Highlights
- Total revenue: NOK 118.2 million (2024: NOK 108.1 million), +9%
- Sales revenue: NOK 112.6 million (2024: NOK 104.4 million), +8%
- Constant currency sales: NOK 114.9 million, +11%
- EBITDA: NOK 12.0 million (2024: NOK 5.1 million)
- Profit before tax: NOK 12.2 million (2024: NOK 10.6 million)
The Company returned to growth in 2025, supported by commercial execution, improved product mix and disciplined cost management.
Financial Position
- Net cash flow: NOK 5.4 million in Q4; NOK 16.8 million year-to-date (2024: NOK -9.9 million)
- Cash and cash equivalents: NOK 187.8 million
- Additional liquid interest-bearing funds: NOK 76.9 million
- No interest-bearing debt
ArcticZymes maintains a strong balance sheet, providing financial flexibility to support continued organic expansion, targeted portfolio investments and disciplined evaluation of strategic opportunities.
Business Segment Performance
Biomanufacturing
- Q4 revenue: NOK 15.2 million (+25% YoY), representing 45% of total sales
- Full-year revenue growth: +23%
- GMP-grade product sales increased approximately 106% YoY in Q4
- SAN portfolio achieved its second-highest annual sales level (after 2022)
Growth was supported by increasing adoption among CDMO customers and progression of clients into later-stage development programs.
Molecular Tools
- Q4 revenue: NOK 18.9 million (+55% YoY), representing 55% of total sales
- Full-year revenue declined 6% versus 2024
Q4 performance reflects increased activity from a key account combined with broader customer growth, partially offsetting reduced purchasing earlier in the year.
CEO Commentary
"Q4 marked a strong finish to 2025, with 39% sales growth and a significant improvement in EBITDA compared with last year," said Michael Akoh, CEO of ArcticZymes Technologies ASA. "We returned to growth in 2025 and enter 2026 with solid commercial momentum, improving profitability and a strong financial position to support further expansion."
Outlook
ArcticZymes remains focused on driving sustainable growth through:
- Continued scaling of Biomanufacturing, with increased GMP-grade penetration
- Expansion of CDMO partnerships to build long-term revenue visibility
- Broader enzyme application development, including metagenomics
- Further build-out of the RNA enzyme portfolio, including the launch of ET-N1
With a strengthened commercial platform, expanding application footprint and a solid balance sheet, the Company is well positioned for continued growth in 2026 and beyond.
-Ends-
Presentation and Webcast
The Company will host a virtual Q4 and FY 2025 presentation for investors, analysts and media at 10:00 CET on Thursday, February 12, 2026.
The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and CCO Paul Blackburn.
The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/XRgPIoZrlRfhnjAmevVbeQ or www.arcticzymes.com. It will be possible to post questions through the webcast console.
The report for Q4 and FY 2025 will be available on www.newsweb.no and on the company's homepage www.arcticzymes.com from 07.00 CET on February 12, 2026.
For more information, please contact:
| ArcticZymes Technologies ASA |
|
| CEO, Michael B. Akoh CFO, Børge Sørvoll | Tel: +46 (0) 70 262 37 15 Tel: +47 95 29 01 87 ir@arcticzymes.com |
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Listed on the Oslo Stock Exchange since 2005. Its headquarters are based in Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.
For more information, please visit the website: www.arcticzymes.com